Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026
Rhea-AI Summary
Aclaris Therapeutics (NASDAQ: ACRS) will release full Phase 1a results for its anti-TSLP/IL-4R bispecific antibody ATI-052 and announce lead indication selection for its ITK/JAK3 inhibitor ATI-2138 before markets open on April 28, 2026.
The company will host a webcast and conference call with slides on April 28, 2026 at 8:30 AM EST; the live and archived webcast will be available on the company Events page and archived for 30 days.
Positive
- None.
Negative
- None.
News Market Reaction – ACRS
In the Apr 28 session, ACRS declined 4.31%, reflecting a moderate negative market reaction. Argus tracked a peak move of +5.1% during that session. Argus tracked a trough of -8.7% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 08 | Conference participation | Neutral | +5.3% | Announced participation in H.C. Wainwright inflammatory skin disease virtual conference. |
| Mar 27 | Clinical data update | Positive | +0.0% | Presented Phase 2a ATI-2138 ePoster with substantial week-12 efficacy improvements. |
| Mar 20 | Clinical presentation | Neutral | -1.3% | Announced upcoming ePoster on Phase 2a ATI-2138 results at AAD 2026. |
| Mar 18 | Trial enrollment complete | Positive | -5.7% | Completed enrollment of 109 patients in Phase 2 bosakitug trial for atopic dermatitis. |
| Mar 03 | Conference participation | Neutral | -0.3% | Planned fireside chat at Leerink Partners 2026 Global Healthcare Conference. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent clinical and conference news has produced mixed reactions, with one notable selloff on a positive Phase 2 enrollment milestone.
Over the past two months, Aclaris has issued a steady flow of pipeline and investor-relations updates. Conference participation on Mar 10, 2026 and Apr 14, 2026 produced small to moderate share moves. Clinical communications around ATI-2138 at the 2026 AAD meeting highlighted encouraging Phase 2a data but generated flat to modestly negative reactions. Completion of Phase 2 enrollment for bosakitug with 109 patients on Mar 18, 2026 coincided with a sharper -5.67% decline, showing the stock has occasionally sold off on seemingly constructive clinical progress. Today’s announcement fits this pattern of pipeline-focused catalysts.
Key Terms
phase 1a medical
multiple ascending dose medical
bispecific antibody medical
itk/jak3 inhibitor medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
WAYNE, Pa., April 27, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it will provide the full results from its Phase 1a single and multiple ascending dose trial of its anti-TSLP/IL-4R bispecific antibody ATI-052 and the results of its lead indication selection process for its ITK/JAK3 Inhibitor ATI-2138 before the opening of the financial markets tomorrow, April 28, 2026.
Aclaris will host a webcast and conference call with slides tomorrow morning at 8:30 AM EST to discuss these updates. The live and archived webcast will be available on the Events page of the Company’s website: https://investor.aclaristx.com/events. The webcast will be archived on the same page for 30 days following the event. If you would rather access the call via telephone: To register and receive a dial in number and unique PIN to access the live conference call, please follow this link to register online. Upon registering you will receive the dial-in info and a unique PIN to join the call as well as an email confirmation with the details.
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “anticipate,” “believe,” “expect,” “intend,” “may,” “plan,” “potential,” “will,” and similar expressions, and are based on Aclaris’ current beliefs and expectations. These forward-looking statements include expectations related to the timing of the announcement related to the ATI-052 Phase 1a SAD/MAD results and the results of its lead indication selection process for ATI-2138. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, risks associated with interim, topline and preliminary data, Aclaris’ reliance on third parties over which it may not always have full control, Aclaris’ ability to enter into strategic partnerships on commercially reasonable terms, the uncertainty regarding the macroeconomic environment and other risks and uncertainties that are described in the Risk Factors section of Aclaris’ Annual Report on Form 10-K for the year ended December 31, 2025, and other filings Aclaris makes with the U.S. Securities and Exchange Commission from time to time. These documents are available under the “SEC Filings” page of the “Investors” section of Aclaris’ website at www.aclaristx.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to Aclaris as of the date of this release, and Aclaris assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com and follow Aclaris and on LinkedIn.
Aclaris Therapeutics Contact:
Will Roberts
Senior Vice President
Corporate Communications and Investor Relations
(484) 329-2125
wroberts@aclaristx.com
